CellCreep Biotech has platform technologies for novel High Cell Density Cultivation (HCDC) for Mammalian cell lines for Monoclonal Antibody expression (Up to 70 to 100 million cells /ml).
CellCreep Biotech team has a rich experience in the field of clone development and bioprocess technology
with individual achievements. The technologies are under development would contribute a lot to the company's growth and also to human society
A basket of biosimilar products are under various stages of development with our collaborators.